OBJECTIVES: Several microRNAs (miRNAs) have been identified as potential circulating biomarkers in a number of different cancers including colorectal cancer (CRC). This study aims to assess the diagnostic performance of circulating miRNAs in detecting CRC through meta-analysis of all eligible relevant studies. MATERIALS AND METHODS: An extensive literature search was performed and studies that estimated the diagnostic accuracy of miRNAs in CRC were identified. Data from the eligible studies were collected and pooled; sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratios, weighted symmetric summary ROC curve and the area under the curve (AUC) were calculated. Heterogeneity was evaluated using the Q-test and I(2)-statistics. In addition, subgroup analyses and meta-regression analyses were carried out to explore the potential sources of significant heterogeneity. RESULTS: A total of 16 studies were included in the meta-analysis according to the inclusion criteria. The overall analysis showed that circulating miRNAs have a relatively good diagnostic performance in CRC, with a sensitivity of 78%, a specificity of 79% and an AUC of 0.87. Subgroup analyses showed that a single miRNA-21 test, as opposed to a panel miRNAs test, significantly improved the diagnostic accuracy with 83.4% sensitivity, 91.6% specificity, and AUC increasing to 0.94. CONCLUSION: Circulating miRNAs, especially miRNA-21, are promising diagnostic biomarkers in CRC. However, more prospective studies are required to further explore their diagnostic role and their usefulness in clinical practice.
OBJECTIVES: Several microRNAs (miRNAs) have been identified as potential circulating biomarkers in a number of different cancers including colorectal cancer (CRC). This study aims to assess the diagnostic performance of circulating miRNAs in detecting CRC through meta-analysis of all eligible relevant studies. MATERIALS AND METHODS: An extensive literature search was performed and studies that estimated the diagnostic accuracy of miRNAs in CRC were identified. Data from the eligible studies were collected and pooled; sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratios, weighted symmetric summary ROC curve and the area under the curve (AUC) were calculated. Heterogeneity was evaluated using the Q-test and I(2)-statistics. In addition, subgroup analyses and meta-regression analyses were carried out to explore the potential sources of significant heterogeneity. RESULTS: A total of 16 studies were included in the meta-analysis according to the inclusion criteria. The overall analysis showed that circulating miRNAs have a relatively good diagnostic performance in CRC, with a sensitivity of 78%, a specificity of 79% and an AUC of 0.87. Subgroup analyses showed that a single miRNA-21 test, as opposed to a panel miRNAs test, significantly improved the diagnostic accuracy with 83.4% sensitivity, 91.6% specificity, and AUC increasing to 0.94. CONCLUSION: Circulating miRNAs, especially miRNA-21, are promising diagnostic biomarkers in CRC. However, more prospective studies are required to further explore their diagnostic role and their usefulness in clinical practice.
Authors: Manal S Fawzy; Eman A Toraih; Afaf Ibrahiem; Hala Abdeldayem; Amany O Mohamed; Mohamed M Abdel-Daim Journal: PLoS One Date: 2017-11-01 Impact factor: 3.240
Authors: Zixu Yuan; Kelsey Baker; Mary W Redman; Lei Wang; Scott V Adams; Ming Yu; Brandon Dickinson; Karen Makar; Neli Ulrich; Jürgen Böhm; Michelle Wurscher; Maria Westerhoff; Steve Medwell; Ravi Moonka; Mika Sinanan; Alessandro Fichera; Kathy Vickers; William M Grady Journal: Br J Cancer Date: 2017-08-15 Impact factor: 7.640